Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dobutamine or milrinone (Eli Lilly and Company)
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The phrase "dobutamine or milrinone" refers to the selection of intravenous inotropic agents used for the management of patients with severe, decompensated congestive heart failure, particularly those awaiting cardiac transplantation (UNOS Status 1B). Dobutamine is a synthetic catecholamine and a potent beta-1 adrenergic receptor agonist that increases myocardial contractility and cardiac output. Milrinone is a bipyridine phosphodiesterase 3 (PDE3) inhibitor that increases intracellular cyclic adenosine monophosphate (cAMP), leading to enhanced contractility and systemic vasodilation (inodilator effect). In clinical trial contexts, such as the TMAC study for nesiritide, these drugs are used as continuous infusions to provide hemodynamic support as part of standard care.
- Brand names
- DobutrexPrimacor
- Other names
- dobutaminemilrinone
02
Targets
PDE3ADRB1 (β1)
Beyond the preview
Go deeper on dobutamine or milrinone (Eli Lilly and Company).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dobutamine or milrinone (Eli Lilly and Company).